into action
"Pharmacyclics' HDAC inhibitor has good oral bioavailability and is well tolerated at doses that inhibit the target enzyme."
Samir D. Undevia, M.D. University of ChicagoSection of Hematology/Oncology
We are leveraging our small-molecule drug development expertise to build a pipeline in oncology and immune mediated diseases based on novel targets, pathways and mechanisms. We have several products in the pipeline, each derived from structure-based research. Multiple histone deacetylase (HDAC) inhibitors, both broad spectrum (PCI-24781) – meaning they target all forms of HDAC enzymes – and isoform selective (HDAC8), are being developed for solid tumors and lymphomas. Our Factor VIIa inhibitor, PCI-27483, possesses a novel mechanism of action that targets both the tumor itself and thrombotic disease that often occurs in patients with cancer. Finally, our lead BTK inhibitor PCI-32765 shows promising activity in animal models of lymphoma and rheumatoid arthritis.
The company has substantial experience in conducting worldwide clinical research and has internal capabilities in regulatory affairs, biometrics and quality assurance.